Blues Brief



For oncology providers

Clinical information will be used to validate answers in e-referral



Beginning June 2021, we'll pend some authorization requests that would usually be auto-approved based on responses to questionnaires in the e-referral system. We'll review and verify that the clinical information provided supports your responses to the questionnaire and make a determination on the request. For more information, see Page 36 of the May-June 2021 BCN Provider News or the May 2021 issue of The Record.

RC Claim Assist update

Starting May 1, 2021, you must go through Provider Secured Services to access RC Claim Assist. For more information, see Page 32 of the May-June 2021 BCN Provider News or the May 2021 issue of The Record.

Starting in August, Michigan Pro outpatient facilities must bill NDCs with NOCs or commercial claims will reject

Starting Aug. 1, 2021, when outpatient facilities bill for drugs for Blue Cross commercial members on an outpatient claim with a HCPCS code that has a not otherwise classified code, they must also include the National Drug Code. HCPCS codes for NOC drugs billed without this information will be rejected. For more details, see the May 2021 issue of The Record.

Holiday office closings

Blue Cross and BCN offices will be closed Monday, July 5 (Independence Day).

Billing policy and guidelines Policy for intensity modulated radiation therapy

When billing for intensity modulated radiation therapy, or IMRT, follow the guidelines in accordance with the new Blue Cross Blue Shield of Michigan policy. This policy has been adopted to align billing requirements with industry and Centers for Medicare & Medicaid Services standards. For more information about the IMRT policy and guidelines, see Page 34 of the May-June 2021 BCN Provider News or the April 2021 issue of The Record.

Recommendations for submitting authorization requests for medical oncology drugs to AIM

Follow these recommendations for submitting authorization requests for medical oncology drugs to AIM Specialty Health® to ensure a more efficient authorization review process:

- Wait to submit the request until you have all the pertinent information, including but not limited to, tumor testing results, information on tumor staging and prior therapy regimens.
- Provide all the clinical information needed for clinical review, including the rationale for the requested regimen.
- Be sure the phone number provided is accurate if AIM needs to contact you to schedule a peer-topeer consultation for more information to establish medical necessity.


This information applies to all Blue Cross PPO, Medicare Plus BlueSM PPO, BCN HMOSM and BCN AdvantageSM members whose plans require authorization of medical oncology drugs by AIM.

For more information, see Page 27 of the July-August 2020 BCN Provider News or the June 2020 issue of The Record.

Continued on the next page

Articles apply to all lines of business unless noted by the icons below:







Blues Brief



For oncology providers

Continued from front page

Oncology Provider Resources

Located on ereferrals.bcbsm.com:

Oncology management program FAQs **ereferrals.bcbsm.com** → BCN or Blue Cross→ AIM-Managed Procedures → Oncology management program: Frequently asked questions for providers

Medical Benefit Drugs page – BCN ereferrals.bcbsm.com \rightarrow BCN \rightarrow Medical Benefit Drugs

Medical Benefit Drugs page – Blue Cross ereferrals.bcbsm.com \rightarrow Blue Cross \rightarrow Medical Benefit Drugs

Blue Cross and BCN utilization management medical drug list

ereferrals.bcbsm.com \rightarrow Blue Cross or BCN \rightarrow Medical Benefit Drugs → Blue Cross and BCN utilization management medical drug list (PDF)

Located on bcbsm.com/providers:

Medical Drug and Step Therapy Prior Authorization List for Medicare Plus BlueSM and BCN AdvantageSM members **bcbsm.com/providers** → Quick Links → Medicare Advantage → BCN Advantage HMO-POS resources → BCN Advantage HMO-POS and BCN Advantage medical drug policies and forms \rightarrow Medicare Advantage Medical Drug Prior Authorization and Step Therapy List (PDF) or

Medicare Advantage PPO medical drug policies and forms → Medicare Advantage Medical Drug Prior Authorization and Step Therapy List (PDF)

Questions about non-oncology medications for drugs in the NovoLogix system: specialtypharmacyinquiry@bcbsm.com

Rx updates

Submit prior authorization requests for **CAR-T** cell therapy drugs to NovoLogix for **Medicare Advantage inpatient admissions** See Page 8 of the July-August 2021 BCN Provider News or the December 2020 issue of The Record.

Abecma requires prior authorization MA PPO for Medicare Advantage members See Page 6 of the July-August 2021 BCN Provider News or the May 2021 issue of The Record.

We've made changes to preferred products for drugs covered under the medical benefit for most members

See Page 29 of the May-June 2021 BCN Provider News or the May 2021 issue of The Record.

Additional medications will require prior authorization for most members, starting **May 24**

See Page 16 of the July-August 2021 BCN Provider News or the May 2021 issue of The Record.

Additional medical benefit drugs to PPO require prior authorization for some **Blue Cross commercial members** See the May 2021 issue of *The Record*.

Reminder: Bill HCPCS code J3590 for PPO off-label use of Avastin® for Blue Cross commercial members

See the January 2021 issue of The Record.

Additional drugs covered under MA PPO Medicare Part B now available at retail pharmacies

See Page 12 of the May-June 2021 BCN Provider News or the April 2021 issue of The Record.

Articles apply to all lines of business unless noted by the icons below:







